NGEN
NervGen Pharma Corp.NASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage limited
$1.63-5.78%
Close Oct 13, 2026
- Market cap
- $150.68M
- 1 month
- -25.7%
- 3 months
- -3.6%
- 1 year
- —
- Dividend
- No dividends on record
- Short interest
- 6.1% of float5.8M shares · settled Sep 30, 2026 · +6.2% since Sep 15, 2026 · FINRA
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if NGEN is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
17 top institutions tracked
as of 2026-Q2 (filed 2026-08-14)
Insider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 0
Largest 13-F holders · Q2 2026
62 filers reported a long position in NGEN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Empery Asset Management, LP | $8.2M | 4M | New |
| Rock Springs Capital Management LP | $2.5M | 1.2M | New |
| DAFNA Capital Management LLC | $2.2M | 1.1M | New |
| Ghisallo Capital Management LLC | $2.1M | 1M | New |
| ARMISTICE CAPITAL, LLC | $1.4M | 678K | New |
| LMR Partners LLP | $1.2M | 600K | New |
| MARSHALL WACE, LLP | $898.1K | 436K | +117.6% |
| UBS Group AG | $782.2K | 379.7K | +517.3% |
| Stonepine Capital Management, LLC | $559.7K | 271.7K | New |
| JANE STREET GROUP, LLC | $557.7K | 270.8K | New |
Get the Full Analysis for NGEN
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.